Puma Biotechnology Inc (PBYI) News
Filter PBYI News Items
PBYI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PBYI News Highlights
- For PBYI, its 30 day story count is now at 12.
- Over the past 26 days, the trend for PBYI's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- AL, BEAT and CM are the most mentioned tickers in articles about PBYI.
Latest PBYI News From Around the Web
Below are the latest news stories about PUMA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate PBYI as an investment opportunity.
Freeline (FRLN) Shares Rise on Merger Agreement With SynconaFreeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise. |
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock DownThe FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls. |
Here's Why You May Invest in Puma Biotechnology (PBYI) StockHere, we discuss some reasons why investing in Puma Biotechnology (PBYI) stock now may turn out to be a more prudent move than ever. |
Read This Before Judging Puma Biotechnology, Inc.'s (NASDAQ:PBYI) ROEOne of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will... |
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSCThe FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises. |
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)LOS ANGELES, November 06, 2023--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 1, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 15,000 shares of Puma common stock to one new non-executive employee. |
Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag EstimatesPuma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance. |
Q3 2023 Puma Biotechnology Inc Earnings CallQ3 2023 Puma Biotechnology Inc Earnings Call |
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2023 Earnings Call TranscriptPuma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2023 Earnings Call Transcript November 2, 2023 Puma Biotechnology, Inc. misses on earnings expectations. Reported EPS is $0.12 EPS, expectations were $0.15. Operator: Good afternoon. My name is Camilla, and I will be your conference call operator today. [Operator Instructions] As a reminder, this call is being recorded. I would […] |
Puma Biotechnology Inc (PBYI) Reports Positive Net Income and Cash Flow in Q3 2023Company's product revenue for the first nine months of 2023 reaches $149.9 million |